We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC

Delisted

BCLI was delisted on the 17th of July, 2025.

46 hedge funds and large institutions have $1.05M invested in BRAINSTORM CELL THERAPUTC in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $928K → $1.05M (+$125K)

0.16% less ownership

Funds ownership: 0.71%0.55% (-0.16%)

13% less funds holding

Funds holding: 5346 (-7)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

52% less call options, than puts

Call options by funds: $23K | Put options by funds: $48K

Holders
46
Holders Change
-7
Holders Change %
-13.21%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
8
Reduced
11
Closed
16
Calls
$23K
Puts
$48K
Net Calls
-$25K
Net Calls Change
+$714K
Name Holding Trade Value Shares
Change
Change in
Stake
LPL Financial
51
LPL Financial
California
-$8.29K -2,763 Closed
TSS
52
Two Sigma Securities
New York
-$8.06K -2,685 Closed
Jane Street
53
Jane Street
New York
-$6.12K -2,038 Closed
MCP
54
Mirador Capital Partners
California
-$5.31K -1,768 Closed
XT
55
XTX Topco
Cayman Islands
-$4.9K -1,633 Closed
AWM
56
AE Wealth Management
Kansas
-$2.89K -961 Closed
CWA
57
Centennial Wealth Advisory
Michigan
-$2.4K -800 Closed
Charles Schwab
58
Charles Schwab
California
-$2.26K -752 Closed
WT
59
Washington Trust
Rhode Island
-$500 -167 Closed
Royal Bank of Canada
60
Royal Bank of Canada
Ontario, Canada
-$288 -96 -73%
HI
61
Harbour Investments
Wisconsin
-$159 -53 Closed

BCLI Hedge Fund Activity: Q4 2023 in Review

46 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2023, worth a combined $1.05M — up 13% from $928K a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of BCLI and 9 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Weaver Consulting Group, adding an estimated $20K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $41K sold.

  • 46 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2023, down from 53 in Q3 2023.
  • Funds reported $1.05M of BRAINSTORM CELL THERAPUTC stock for Q4 2023, up 13% quarter-over-quarter.
  • 9 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2023 and 16 closed out, a net change of -7 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2023 was Weaver Consulting Group, an estimated $20K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q4 2023 was Renaissance Technologies, an estimated $41K sold.

Based on aggregated 13F filings for Q4 2023.